🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in Turkey / NCT07604259
Starting soon Not applicable

Comparison of QLB and TFP Block for Postoperative Analgesia in Laparoscopic Inguinal Hernia

NCT07604259 · tracked via the Priya Life Science Turkey tracker
Phase
Not applicable
Started
2026-06-10
Last updated
2026-05-22

Condition(s) studied

İnguinal HerniaPost Operative Pain

Investigational drug(s) / intervention(s)

Lateral Quadratus Lumborum BlockTransversalis Fascia Plane BlockPort Site Infiltration

Lateral Quadratus Lumborum Block: Bilateral ultrasound-guided lateral QLB with 20 mL of 0.25% bupivacaine per side (total 40 mL). Plus, 10 mL of 0.25% bupivacaine infiltration at trocar insertion sites.

Transversalis Fascia Plane Block: Bilateral ultrasound-guided TFP block with 20 mL of 0.25% bupivacaine per side (total 40 mL). Plus, 10 mL of 0.25% bupivacaine infiltration at trocar insertion sites.

Port Site Infiltration: Local infiltration of 20 mL of 0.25% bupivacaine at the trocar insertion sites.

Study summary

This randomized controlled trial aims to compare the effects of ultrasound-guided lateral Quadratus Lumborum Block (QLB) and Transversalis Fascia Plane (TFP) block on postoperative analgesia in patients undergoing laparoscopic inguinal hernia repair. Ninety patients will be randomly assigned to one of three groups: Group QLB, Group TFP, or Group Control. The primary objective is to compare postoperative pain scores (NRS) at various time points within the first 24 hours. Secondary objectives include evaluating the need for rescue analgesia, total tramadol consumption, and the incidence of opioid-related side effects.

Eligibility

Sex
ALL
Min age
18 Years
Max age
65 Years
Healthy volunteers
No
Inclusion Criteria: * Scheduled for elective laparoscopic inguinal hernia repair. * American Society of Anesthesiologists (ASA) physical status I, II, or III. * Age between 18 and 65 years. * Provided written informed consent. Exclusion Criteria: * History of allergy to local anesthetics. * Presence of coagulopathy. * Signs of infection at the intended block application site. * Body Mass Index (BMI) ≥ 35 kg/m². * History of chronic opioid use. * Presence of neurological disease. * Refusal to participate in the study.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Istanbul Medipol University Istanbul Turkey (Türkiye)

More Medipol University trials in Turkey

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07604259 on ClinicalTrials.gov ↗ ← All trials in Turkey